Safety of the Geneva Cocktail, a Cytochrome P450 and P-Glycoprotein Phenotyping Cocktail, in Healthy Volunteers from Three Different Geographic Origins.
ATP Binding Cassette Transporter, Subfamily B, Member 1
/ genetics
Adolescent
Adult
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Enzyme System
/ genetics
Czech Republic
Drug Combinations
Ethiopia
Female
Gene Expression Regulation
/ drug effects
Genotype
Healthy Volunteers
Humans
Male
Oman
Pharmaceutical Preparations
/ metabolism
Substrate Specificity
Young Adult
Journal
Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
28
8
2020
medline:
15
9
2021
entrez:
28
8
2020
Statut:
ppublish
Résumé
INTRODUCTION AND OBJECTIVE: Cytochrome P450 enzymes are the major drug-metabolizing enzymes in humans and the importance of drug transport proteins, in particular P-glycoprotein, in the variability of drug response has also been highlighted. Activity of cytochrome P450 enzymes and P-glycoprotein can vary widely between individuals and genotyping and/or phenotyping can help assess their activity. Several phenotyping cocktails have been developed. The Geneva cocktail is composed of a specific probe for six different cytochrome P450 enzymes and one for P-glycoprotein and was used in the context of a research aiming at exploring genotypes and phenotypes in distinct human populations (NCT02789527). The aim of the present study is to solely report the safety results of the Geneva cocktail in the healthy volunteers of these populations. The Geneva cocktail is composed of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, and fexofenadine. The volunteers fasted and avoided drinking caffeine-containing beverages or food and grapefruit juice overnight before receiving the cocktail orally. They provided blood spots for the probes' concentrations at 2, 3, and 6 h after ingestion and were asked about adverse events. A total of 265 healthy adult volunteers were included from Ethiopia, Oman, and the Czech Republic. The mean plasma concentrations at the 2-h sampling time of each probe drug in the total sample were: 1663 ng/mL for caffeine, 8 ng/mL for bupropion, 789 ng/mL for flurbiprofen, 6 ng/mL for dextromethorphan, 2 ng/mL for midazolam, 35 ng/mL for fexofenadine, and 103 ng/mL for omeprazole. Four adverse events were observed representing an occurrence of 1.5%. All these events were categorized as mild to moderate, non-serious, and resolved spontaneously. A causal link with the cocktail cannot be excluded because of the temporal relationship but is at most evaluated as possible according to the World Health Organization-Uppsala Monitoring Centre causal assessment system. In this research, healthy volunteers from three different human populations were phenotyped with the Geneva cocktail. Four adverse events were observed, confirming the safety of this cocktail that is given at lower than clinically relevant doses and therefore results in concentrations lower than those reported to cause adverse events.
Identifiants
pubmed: 32851583
doi: 10.1007/s40264-020-00983-8
pii: 10.1007/s40264-020-00983-8
pmc: PMC7575470
doi:
Substances chimiques
ATP Binding Cassette Transporter, Subfamily B, Member 1
0
Cytochrome P-450 Enzyme Inhibitors
0
Drug Combinations
0
Pharmaceutical Preparations
0
Cytochrome P-450 Enzyme System
9035-51-2
Banques de données
ClinicalTrials.gov
['NCT02789527']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1181-1189Références
Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci. 2005;360(1460):1563–70.
doi: 10.1098/rstb.2005.1685
Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392(6):1093–108.
doi: 10.1007/s00216-008-2291-6
Elewa H, Wilby KJ. A review of pharmacogenetics of antimalarials and associated clinical implications. Eur J Drug Metab Pharmacokinet. 2017;42(5):745–56.
doi: 10.1007/s13318-016-0399-1
Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit. 2004;26(2):180–5.
doi: 10.1097/00007691-200404000-00017
de Andrés F, Lerena LA. Simultaneous determination of cytochrome P450 oxidation capacity in humans: a review on the phenotyping cocktail approach. Curr Pharm Biotechnol. 2016;17(13):1159–80.
doi: 10.2174/1389201017666160926150117
Bosilkovska M, Samer C, Déglon J, Thomas A, Walder B, Desmeules J, et al. Evaluation of mutual drug-drug interaction within Geneva cocktail for cytochrome P450 phenotyping using innovative dried blood sampling method. Basic Clin Pharmacol Toxicol. 2016;119(3):284–90.
doi: 10.1111/bcpt.12586
Bosilkovska M, Samer CF, Déglon J, Rebsamen M, Staub C, Dayer P, et al. Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther. 2014;96(3):349–59.
doi: 10.1038/clpt.2014.83
The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf . Accessed 29 Apr 2020.
Bosilkovska M, Clément M, Dayer P, Desmeules J, Daali Y. Incorporation of flurbiprofen in a 4-drug cytochrome p450 phenotyping cocktail. Basic Clin Pharmacol Toxicol. 2014;115(5):465–6.
doi: 10.1111/bcpt.12231
Lloret-Linares C, Bosilkovska M, Daali Y, Gex-Fabry M, Heron K, Bancila V, et al. Phenotypic assessment of drug metabolic pathways and P-glycoprotein in patients treated with antidepressants in an ambulatory setting. J Clin Psychiatry. 2018;79(2):16m11387.
doi: 10.4088/JCP.16m11387
Lloret-Linares C, Rollason V, Lorenzini KI, Samer C, Daali Y, Gex-Fabry M, et al. Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study. Pharmacol Res. 2017;118:104–10.
doi: 10.1016/j.phrs.2016.07.002
Wikoff D, Welsh BT, Henderson R, Brorby GP, Britt J, Myers E, et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol. 2017;109(Pt 1):585–648.
doi: 10.1016/j.fct.2017.04.002
Kuate C, Gélisse P, Baldy-Moulinier M, Crespel A. Bupropion-induced epileptic seizures. Rev Neurol (Paris). 2004;160(6–7):701–3.
doi: 10.1016/S0035-3787(04)71021-8
Goren JL, Levin GM. Mania with bupropion: a dose-related phenomenon? Ann Pharmacother. 2000;34(5):619–21.
doi: 10.1345/aph.19313
Laib AK, Brünen S, Pfeifer P, Vincent P, Hiemke C. Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion. Ther Drug Monit. 2014;36(4):473–9.
doi: 10.1097/FTD.0000000000000042
Hamdy RC, Bird A, Le Gallez P, Hill J, Hind ID. A multiple dose pharmacokinetic and tolerance study of once daily 200 mg sustained-release flurbiprofen capsules in young and very elderly patients. Eur J Clin Pharmacol. 1990;39(3):267–70.
doi: 10.1007/BF00315108
Siu A, Drachtman R. Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain. CNS Drug Rev. 2007;13(1):96–106.
doi: 10.1111/j.1527-3458.2007.00006.x
Franken LG, de Winter BCM, Masman AD, van Dijk M, Baar FPM, Tibboel D, et al. Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients. Br J Clin Pharmacol. 2018;84(2):320–30.
doi: 10.1111/bcp.13442
Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther. 1992;51(6):715–28.
doi: 10.1038/clpt.1992.84
Meeves SG, Appajosyula S. Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol. 2003;112(4 Suppl.):S69–77.
doi: 10.1016/S0091-6749(03)01879-7
Smith SM, Gums JG. Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opin Drug Metab Toxicol. 2009;5(7):813–22.
doi: 10.1517/17425250903044967
Forgerini M, Mieli S, de Mastroianni PC. Safety assessment of omeprazole use: a review. Sao Paulo Med J. 2018;136(6):557–70.
doi: 10.1590/1516-3180.2018.0019220318
Clissold SP, Campoli-Richards DM. Omeprazole: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs. 1986;32(1):15–47.
doi: 10.2165/00003495-198632010-00002